1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Huons Global Co., Ltd.

Huons Global Co., Ltd.

084110.KQ
Huons Global Co., Ltd.KR flagKOSDAQ
26,600.00
KRW
-400.00
- -
324.69BMarket Cap
Huons Global Co., Ltd.
084110.KQ
(KOSDAQ)

Recent

price

26,600.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
17,312.61
20,799.6
24,354.52
24,547.71
26,727.73
9,174.92
13,953.92
25,788.19
30,123.94
35,752.4
41,675.1
46,178.5
54,060.69
61,921.24
66,644.95
69,557.69
69,357.04
Revenue per Share
-348.53
879.8
1,211.1
2,697.52
3,068.33
4,540.43
43,864.93
2,051
2,299.54
2,120.63
3,401.9
321
-4,903
3,134
2,113
2,367
1,948.65
Basic EPS, GAAP
-367.25
1,879.85
1,387.18
1,024.18
2,556.67
5,454.3
-1,008.96
88.5
-42.45
2,370.04
2,058.28
-7,722.99
-967.85
1,548.3
-2,878.93
3,425.53
3,452.68
Free Cash Flow per Basic Share
61.66
158.96
178.56
213.53
308.76
633.74
660.06
508.13
804.4
962.55
895.5
813.63
963.84
1,590.53
1,277.8
2,101.86
1,450.06
Dividend per Share
9,487.57
10,115.08
10,902.26
11,838.76
13,989.51
17,294.46
53,776.58
8,584.28
10,146.54
11,846.01
15,127.9
15,214.18
10,021.46
12,439.26
14,042.36
19,609.12
19,902.04
Book Value per Share
13,538.54
14,616.72
15,600.12
18,376.05
26,741.06
32,736.32
21,980.52
23,477.2
27,294.73
30,592.79
36,142.74
53,397.46
54,817.27
64,050.69
69,020.41
76,066.09
76,349.16
Tangible Book Value per Share
5
5
6
6
7
7
12
13
13
13
13
12
12
12
12
12
12
Basic Weighted Avg Shares
94,128
113,122
134,072
158,183
182,343
65,440
163,712
323,946
378,670
449,423
523,048
574,648
664,365
758,380
813,461
847,453
845,302
Sales/Revenue/Turnover
-0.17
7.04
11.02
17.66
16.51
18.38
17.65
19.2
17.95
16.22
17.06
13.25
13.06
15.29
11.97
10.71
8.8
Operating Margin (%)
14,615
9,069
8,831
8,857
10,570
7,570
7,938
12,033
15,847
20,662
25,586
29,321
33,641
35,980
40,311
45,437
47,815
Depreciation Expense
-1,895
4,785
6,667
17,383
20,933
32,384
514,638
25,764
28,906
26,657
42,696
3,995
-60,254
38,384
25,791
28,838
23,750
Net Income, GAAP
- -
12.82
26.61
5.59
16.28
29.76
24.64
23.39
20.68
19.4
18.56
48.07
5,148.66
22.57
25.71
22.73
24.78
Effective Tax Rate (%)
-2.01
4.23
4.97
10.99
11.48
49.49
314.36
7.95
7.63
5.93
8.16
0.7
-9.07
5.06
3.17
3.4
2.81
Profit Margin (%)
24,759
41,948
40,599
45,593
98,068
119,816
129,189
129,763
136,116
143,154
189,950
271,518
243,664
290,056
269,880
293,059
268,277
Working Capital
27,353
31,517
25,544
9,990
5,500
2,700
11,461
14,838
17,000
15,816
39,120
68,462
72,473
70,085
100,464
102,638
85,966
LT Debt
78,181
83,208
92,915
125,237
188,377
239,329
453,898
490,997
538,633
581,799
655,399
851,120
785,876
910,677
964,165
1,091,225
1,095,967
Total Equity
- -
5.18
7.35
15.93
12.53
3.33
5.48
8.9
9.28
9.29
9.63
4.03
-400.29
8.02
5.96
5.27
4.18
Return on Invested Capital (%)
- -
6.25
7.22
11
12.4
12.44
96.16
0.5
-0.5
-0.72
-0.63
-2.99
-99.23
-0.86
-0.9
-1.44
-2.32
Return on Capital (%)
-3.6
8.98
11.59
25.51
24.38
29.6
136.46
6.97
24.56
19.29
25.21
2.11
-38.56
27.86
15.93
14.06
10.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
196,503
204,623
207,844
LT Borrowings
80,090
100,170
83,775
LT Finance Leases
2,733
2,468
2,192
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
559,090
623,647
808,044

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
602,397
612,738
604,427
Cash, Cash Equivalents & STI
281,392
292,965
286,623
Accounts Receivable, Net
157,522
163,275
146,371
Inventories
142,259
134,448
145,560
Total Current Liabilities
306,835
319,679
336,150
Payables & Accruals
- -
- -
- -
ST Debt
196,503
204,623
207,844
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.53%
11.42%
13.18%
Free Cash Flow
-740.69%
-264.63%
-218.77%
Net Income, GAAP
-42.5%
-376.75%
11.82%
Sales/Revenue/Turnover
35.11%
10.21%
4.18%
Total Cash Common Dividend
24.05%
23.16%
64.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
201,881
209,651
199,421
202,507
813,461
2025
199,105
212,659
211,168
224,521
847,453
2026
196,954
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
893
832
216
- -
2,113
2025
918
32.51
885.09
- -
2,367
2026
499.4
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
600.98
- -
1,277.8
2025
- -
- -
291.04
- -
2,101.86
2026
- -
- -
- -
- -
- -
Similar Companies
Willow Biosciences Inc. (WLLW.TO)
China Health Industries Holdings, Inc. (CHHE)
Lincoln Pharmaceuticals Ltd. (LINCOLN.BO)
Digital Utilities Ventures, Inc. (DUTV)
Golden Biotechnology Corporation (4132.TWO)
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
Business
Huons Global Co., Ltd. is a South Korean healthcare company primarily engaged in the manufacture and distribution of pharmaceutical products. The company offers a comprehensive portfolio including oral solid form products for circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, and chemotherapeutic categories. Additionally, it produces injectable drugs, medical devices such as extracorporeal shockwave lithotriptors and endoscope reprocessors, eye drop products, and biopharmaceutical items. The company operates globally with a strong presence in the domestic South Korean market and is expanding internationally through strategic partnerships and local assembly production models, notably with partners in India. Founded in 1965 and headquartered in Seongnam, South Korea, Huons Global underwent a name change from Huons Co., Ltd. in 2016 to better reflect its expanding business scope. The company operates several subsidiaries, including Huons N, which focuses on health functional foods, and Humedix, specializing in regenerative medicine and aesthetic medical products. Huons N was established in 2025 as an integrated business entity encompassing R&D, manufacturing, and logistics, with product offerings such as customized health functional foods based on individually recognized ingredients. Recently in November 2025, Huons N acquired Biorosette Co., Ltd., a health functional food manufacturer, to enhance manufacturing capabilities and global market reach. Strategically, Huons Global is strengthening its global footprint and production capabilities through collaborations and acquisitions. In late 2025, its subsidiary Huons Meditech signed a local assembly and production collaboration agreement with India's Vasu Group to accelerate market penetration via a Complete Knock Down (CKD) production model. Humedix launched a new human tissue skin booster product, Elravie Re2O, in 2024, expanding the company's aesthetic medicine portfolio through licensing and distribution agreements. Huons also continues to develop biopharmaceutical products, including subcutaneous injection formulations, through its research-focused subsidiaries such as Huonslab and PanGen. The company is positioned in the drug manufacturers industry, specifically in specialty and generic pharmaceuticals, and targets healthcare providers, specialty clinics, and consumers in South Korea and international markets. It leverages advanced manufacturing technologies and proprietary R&D to maintain competitive advantages across its wide-ranging healthcare segments. Overall, Huons Global Co., Ltd. presents a diversified healthcare profile with key offerings spanning pharmaceuticals, medical devices, aesthetics, biopharmaceuticals, and health functional foods, supported by strategic expansions and collaborations to strengthen its global market position.